New drug aramchol aims to reverse fatty liver damage in phase 3 trial
Disease control
Terminated
This study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see …
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC